|
Jay Kleiman, MD, MPA, a cardiologist with thirty years of medical practice and industry experience, has demonstrated leadership in both health policy and medical products development. As Medical Director, Cardiovascular/Metabolic Clinical Research for the G.D. Searle Division of Pharmacia (now Pfizer Corporation), he managed a 7,300-patient interventional cardiology outcomes trial (EXCITE), and a 6,600-patient international phase III heart failure trial (EPHSESUS) that led to a successful NDA submission. Dr. Kleiman also served for ten years as Medical Director, Interventional Cardiovascular Services, for the St. Joseph Hospital in Chicago and most recently served as Vice President, Clinical Affairs at Northfield Laboratories. As an active member of the American College of Cardiology Advocacy Committee since 1990, Dr. Kleiman�s Senate testimony led to a readjustment in the cardiology reimbursement formula. Dr. Kleiman received his MD from the University of Michigan and a Master�s Degree in Public Administration from Harvard University Kennedy School of Government. He also served as a Research Associate at the National Institutes of Health in Bethesda, Maryland, was a medical resident at Georgetown University Medical School, and was a Fellow in Cardiology at Stanford University. As Vasogen�s senior medical officer, Dr. Kleiman is responsible for the overall development of the Company�s cardiovascular products. | 